Comparison of extracorporeal cellular therapy (ELAD(®)) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure

BACKGROUND: Preliminary evidence of safety and efficacy of an extracorporeal cellular therapy (ELAD(®)) has been demonstrated in subjects with acute forms of liver failure. This study compared ELAD with standard of care in Chinese subjects with acute-on-chronic liver failure (ACLF), predominantly se...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Zhongping, Xin, Shaojie, Zhang, Jing, You, Shaoli, Chen, Yu, Liu, Hongling, Zheng, Sujun, Li, Zheng, Ashley, Robert, Millis, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247955/
https://www.ncbi.nlm.nih.gov/pubmed/30532603
http://dx.doi.org/10.2147/HMER.S180246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247955/
https://www.ncbi.nlm.nih.gov/pubmed/30532603
http://dx.doi.org/10.2147/HMER.S180246

Ejemplares similares